Cargando…

Combined Detection of ACTN4 and SCC-Ag is a Promising Serological Biomarker for Cervical Intraepithelial Neoplasia 3 or Worse: A Case–Control Study

PURPOSE: Cervical cancer (CC) is a common malignancy in women. Squamous cell carcinoma antigen (SCC-Ag) and cancer antigen (CA)-125 are widely used to help diagnose CC, but novel tumour markers with superior sensitivity and specificity are needed. α-Actinin 4(ACTN4) is overexpressed in CC, though it...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Bin, Dong, Binhua, Hong, Simei, Wang, Meihua, Dai, Weichao, Zheng, Qingzhu, Wu, Dan, Cao, Yingping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7685365/
https://www.ncbi.nlm.nih.gov/pubmed/33244281
http://dx.doi.org/10.2147/RMHP.S278809
_version_ 1783613170405867520
author Zhu, Bin
Dong, Binhua
Hong, Simei
Wang, Meihua
Dai, Weichao
Zheng, Qingzhu
Wu, Dan
Cao, Yingping
author_facet Zhu, Bin
Dong, Binhua
Hong, Simei
Wang, Meihua
Dai, Weichao
Zheng, Qingzhu
Wu, Dan
Cao, Yingping
author_sort Zhu, Bin
collection PubMed
description PURPOSE: Cervical cancer (CC) is a common malignancy in women. Squamous cell carcinoma antigen (SCC-Ag) and cancer antigen (CA)-125 are widely used to help diagnose CC, but novel tumour markers with superior sensitivity and specificity are needed. α-Actinin 4(ACTN4) is overexpressed in CC, though its diagnostic value for CC is unclear. This study examined the diagnostic value of ACTN4 and SCC-Ag as biomarkers for cervical intraepithelial neoplasia (CIN) 3 or worse. METHODS: Women screened for CC at Fujian Medical University Union Hospital were recruited from 2017.1 to 2018.5. Cervical tissues and blood were collected at the same time. Patients pathologically diagnosed as CIN3+ or NILM/CIN1/CIN2 were classified into the case and control groups, respectively. ACTN4 mRNA and protein levels were detected through quantitative PCR and immunohistochemistry, respectively, and ACTN4 and SCC-Ag concentrations were analysed by ELISA. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood rate (PLR), negative likelihood rate (NLR), and Youden index (YI) of ACTN4 and SCC-Ag were evaluated. The optimum cut-off points for ACTN4 and SCC-Ag were determined by receiver operating characteristic (ROC) curve analysis, and accuracy was evaluated by the area under the ROC curve. RESULTS: In total, 105 patients were classified as CIN3+ cases and 106 as controls. The median ACTN4 levels in case and control tissues were 10.6 and 4.15, respectively. The ACTN4 and SCC-Ag concentrations were significantly higher in cases than controls (P(ACTN4)=0.0007; P(SCC-Ag)=0.0067). The sensitivity, specificity, PPV, NPV, PLR, NLR and YI of ACTN4 were 68.6%, 76.3%, 76.3%, 72.5%, 2.89, 0.41 and 44.9, respectively; SCC-Ag had a similar diagnostic value (P>0.05), and ACTN4 combined with SCC-Ag had a superior diagnostic value (75.6%, 87.5%, 88.6%, 73.7%, 6.05, 0.28, and 63.1, respectively). CONCLUSION: Combined ACTN4 and SCC-Ag detection is a promising serological biomarker for patients with CIN3 or worse.
format Online
Article
Text
id pubmed-7685365
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-76853652020-11-25 Combined Detection of ACTN4 and SCC-Ag is a Promising Serological Biomarker for Cervical Intraepithelial Neoplasia 3 or Worse: A Case–Control Study Zhu, Bin Dong, Binhua Hong, Simei Wang, Meihua Dai, Weichao Zheng, Qingzhu Wu, Dan Cao, Yingping Risk Manag Healthc Policy Original Research PURPOSE: Cervical cancer (CC) is a common malignancy in women. Squamous cell carcinoma antigen (SCC-Ag) and cancer antigen (CA)-125 are widely used to help diagnose CC, but novel tumour markers with superior sensitivity and specificity are needed. α-Actinin 4(ACTN4) is overexpressed in CC, though its diagnostic value for CC is unclear. This study examined the diagnostic value of ACTN4 and SCC-Ag as biomarkers for cervical intraepithelial neoplasia (CIN) 3 or worse. METHODS: Women screened for CC at Fujian Medical University Union Hospital were recruited from 2017.1 to 2018.5. Cervical tissues and blood were collected at the same time. Patients pathologically diagnosed as CIN3+ or NILM/CIN1/CIN2 were classified into the case and control groups, respectively. ACTN4 mRNA and protein levels were detected through quantitative PCR and immunohistochemistry, respectively, and ACTN4 and SCC-Ag concentrations were analysed by ELISA. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood rate (PLR), negative likelihood rate (NLR), and Youden index (YI) of ACTN4 and SCC-Ag were evaluated. The optimum cut-off points for ACTN4 and SCC-Ag were determined by receiver operating characteristic (ROC) curve analysis, and accuracy was evaluated by the area under the ROC curve. RESULTS: In total, 105 patients were classified as CIN3+ cases and 106 as controls. The median ACTN4 levels in case and control tissues were 10.6 and 4.15, respectively. The ACTN4 and SCC-Ag concentrations were significantly higher in cases than controls (P(ACTN4)=0.0007; P(SCC-Ag)=0.0067). The sensitivity, specificity, PPV, NPV, PLR, NLR and YI of ACTN4 were 68.6%, 76.3%, 76.3%, 72.5%, 2.89, 0.41 and 44.9, respectively; SCC-Ag had a similar diagnostic value (P>0.05), and ACTN4 combined with SCC-Ag had a superior diagnostic value (75.6%, 87.5%, 88.6%, 73.7%, 6.05, 0.28, and 63.1, respectively). CONCLUSION: Combined ACTN4 and SCC-Ag detection is a promising serological biomarker for patients with CIN3 or worse. Dove 2020-11-20 /pmc/articles/PMC7685365/ /pubmed/33244281 http://dx.doi.org/10.2147/RMHP.S278809 Text en © 2020 Zhu et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Zhu, Bin
Dong, Binhua
Hong, Simei
Wang, Meihua
Dai, Weichao
Zheng, Qingzhu
Wu, Dan
Cao, Yingping
Combined Detection of ACTN4 and SCC-Ag is a Promising Serological Biomarker for Cervical Intraepithelial Neoplasia 3 or Worse: A Case–Control Study
title Combined Detection of ACTN4 and SCC-Ag is a Promising Serological Biomarker for Cervical Intraepithelial Neoplasia 3 or Worse: A Case–Control Study
title_full Combined Detection of ACTN4 and SCC-Ag is a Promising Serological Biomarker for Cervical Intraepithelial Neoplasia 3 or Worse: A Case–Control Study
title_fullStr Combined Detection of ACTN4 and SCC-Ag is a Promising Serological Biomarker for Cervical Intraepithelial Neoplasia 3 or Worse: A Case–Control Study
title_full_unstemmed Combined Detection of ACTN4 and SCC-Ag is a Promising Serological Biomarker for Cervical Intraepithelial Neoplasia 3 or Worse: A Case–Control Study
title_short Combined Detection of ACTN4 and SCC-Ag is a Promising Serological Biomarker for Cervical Intraepithelial Neoplasia 3 or Worse: A Case–Control Study
title_sort combined detection of actn4 and scc-ag is a promising serological biomarker for cervical intraepithelial neoplasia 3 or worse: a case–control study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7685365/
https://www.ncbi.nlm.nih.gov/pubmed/33244281
http://dx.doi.org/10.2147/RMHP.S278809
work_keys_str_mv AT zhubin combineddetectionofactn4andsccagisapromisingserologicalbiomarkerforcervicalintraepithelialneoplasia3orworseacasecontrolstudy
AT dongbinhua combineddetectionofactn4andsccagisapromisingserologicalbiomarkerforcervicalintraepithelialneoplasia3orworseacasecontrolstudy
AT hongsimei combineddetectionofactn4andsccagisapromisingserologicalbiomarkerforcervicalintraepithelialneoplasia3orworseacasecontrolstudy
AT wangmeihua combineddetectionofactn4andsccagisapromisingserologicalbiomarkerforcervicalintraepithelialneoplasia3orworseacasecontrolstudy
AT daiweichao combineddetectionofactn4andsccagisapromisingserologicalbiomarkerforcervicalintraepithelialneoplasia3orworseacasecontrolstudy
AT zhengqingzhu combineddetectionofactn4andsccagisapromisingserologicalbiomarkerforcervicalintraepithelialneoplasia3orworseacasecontrolstudy
AT wudan combineddetectionofactn4andsccagisapromisingserologicalbiomarkerforcervicalintraepithelialneoplasia3orworseacasecontrolstudy
AT caoyingping combineddetectionofactn4andsccagisapromisingserologicalbiomarkerforcervicalintraepithelialneoplasia3orworseacasecontrolstudy